Android app on Google Play

UBS Survey Shows Signs of Strength for Gilead's (GILD) TAF

May 17, 2013 1:00 PM EDT Send to a Friend
Get Alerts GILD Hot Sheet
Price: $106.10 -1.31%

Rating Summary:
    22 Buy, 5 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 25 | Down: 18 | New: 23
Trade GILD Now!
Join SI Premium – FREE
UBS today maintained a Buy rating on Gilead Sciences (NASDAQ: GILD) and raised its price target to $67.00 (from $63.00). Analyst Matthew Roden sees ongoing strength for its HIV franchise.

"Ahead of the second ph2 result expected near term for tenofovir alafenamide (TAF), a next-gen replacement for Viread, we spoke to 2 HIV experts and conducted a survey of top-volume prescribers to gauge initial receptiveness and expected utilization once available. Results were highly supportive of TAF, but also for GlaxoSmithKline's (NYSE: GSK) dolutegravir, which will compete against GILD's Stribild," said Roden.

For an analyst ratings summary and ratings history on Gilead Sciences (NASDAQ: GILD) click here. For more ratings news on Gilead Sciences click here.

Shares of Gilead Sciences closed at $54.96 yesterday.




You May Also Be Interested In


Related Categories

Analyst Comments, Analyst EPS View, Analyst PT Change

Related Entities

UBS

Add Your Comment